Neuroblastoma (Q54265665)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17586306%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

review article

1 reference

title

Neuroblastoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17586306%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Michael D Hogarty

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17586306%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Rochelle Bagatell

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17586306%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

language of work or name

English

0 references

publication date

1 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17586306%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17586306%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

369

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17586306%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

9579

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17586306%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

2106-2120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17586306%20AND%20SRC:MED&resulttype=core&format=json

Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Neuroblastoma. Mass screening for early detection and its prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Effects of the mass screening of neuroblastoma in Sapporo City

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Neuroblastoma Screening at One Year of Age

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Screening of infants and mortality due to neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Ocular involvement in neuroblastoma: prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients--results of the NBL 90 Study of the French Society of Pediatric Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Epidural compression in neuroblastoma: Diagnostic and therapeutic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Treatment and outcome of 83 children with intraspinal neuroblastoma: the Pediatric Oncology Group experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Antineuronal Antibodies in Patients With Neuroblastoma and Paraneoplastic Opsoclonus-Myoclonus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Effect of steroid and high-dose immunoglobulin therapy on opsoclonus-myoclonus syndrome occurring in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Treatment with intravenously administered immunoglobulins of the neuroblastoma-associated opsoclonus-myoclonus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Special pattern of widespread neuroblastoma with a favourable prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Hyperdiploidy Plus NonamplifiedMYCNConfers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Gene amplification in human neuroblastomas: basic mechanisms and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Detailed molecular analysis of 1p36 in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lackingMYCN amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Chromosome 1p and 11q deletions and outcome in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Variety and complexity of chromosome 17 translocations in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Genetic Staging of Unresectable or Metastatic Neuroblastomain Infants: a Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Neuroblastoma: biological insights into a clinical enigma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Neuroblastoma study NBL 79 of the German Society for Pediatric Oncology. Report after 2 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Spontaneous regression of localized neuroblastoma detected by mass screening

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Mass screening for neuroblastoma: quo vadis? A 9-year experience from the Pediatric Oncology Study Group of the Kyushu area in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Natural course of neuroblastoma detected by mass screening: s 5-year prospective study at a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

N-myc oncogene and stage IV-S neuroblastoma. Preliminary observations on ten cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Bioavailability and dose-dependent anti-tumour effects of 9-cis retinoic acid on human neuroblastoma xenografts in rat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Genetic epidemiology of neuroblastoma: a study of 426 cases at the Institut Gustave-Roussy in France

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Molecular genetic analysis of familial neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Familial neuroblastoma. Case reports, literature review, and etiologic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Abnormal constitutional karyotypes in patients with neuroblastoma: a report of four new cases and review of 47 others in the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Identification and high-resolution mapping of a constitutional 11q deletion in an infant with multifocal neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Ondine's curse and neurocristopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Developmental Genetics of Neuroblastoma12

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Neuroblastoma and ganglioneuroma in a child with multiple neurofibromatosis. Implications for the mutational origin of neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Synchronous neuroblastoma and von Recklinghausen's disease: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Familial neuroblastoma: a three-generation pedigree and a further association with Hirschsprung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Idiopathic congenital central hypoventilation syndrome: Analysis of genes pertinent to early autonomic nervous system embryologic development and identification of mutations in PHOX2b

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Germline PHOX2B mutation in hereditary neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Trk receptor tyrosine kinases: a bridge between cancer and neural development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

trk A gene expression in neuroblastoma. The clinical significance of an immunohistochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Expression and function of TRK-B and BDNF in human neuroblastomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Signaling networks that link cell proliferation and cell fate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Mutations in PIK3CA are infrequent in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Targeted expression of MYCN causes neuroblastoma in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

The MYCN enigma: significance of MYCN expression in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Notch signaling in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

The Hedgehog and Wnt signalling pathways in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Wnt signalling in stem cells and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Regulation of cerebral cortical size by control of cell cycle exit in neural precursors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

beta-Catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Measurement and relevance of neuroblastoma DNA copy number changes in the post-genome era.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Detection of low level genomic alterations by comparative genomic hybridization based on cDNA micro-arrays

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

High-resolution detection and mapping of genomic DNA alterations in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

A Phase I Study of Irinotecan As a 3-Week Schedule in Children With Refractory or Recurrent Solid Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

The somatostatin analogue octreotide inhibits neuroblastoma growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Targeted Radiotherapy With Submyeloablative Doses of 131I-MIBG Is Effective for Disease Palliation in Highly Refractory Neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Differentiating agents in pediatric malignancies: retinoids in neuroblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Retinoid therapy of high-risk neuroblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Vascular endothelial growth factor expression in human neuroblastoma: up-regulation by hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

TNP-470 antiangiogenic therapy for advanced murine neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960983-0

7 January 2021

10.1016/S0140-6736(07)60983-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17586306%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference